Journal of Pharmacology and Pharmacotherapeutics

REVIEW ARTICLE
Year
: 2018  |  Volume : 9  |  Issue : 3  |  Page : 126--130

Phosphodiesterase 7B1 as therapeutic target for treatment of cognitive dysfunctions in multiple sclerosis


Arthi Balsundaram, Darling Chellathai 
 Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India

Correspondence Address:
Arthi Balsundaram
Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai - 600 116, Tamil Nadu
India

Multiple sclerosis (MS) is an autoimmune, chronic degenerative neuroinflammatory disorder affecting younger age groups of the United States of America and Europe. MS prevalence studies in India have shown that India is no longer a low-risk zone. Many studies have shown the seriousness of cognitive impairments (CIs) and its types caused in MS. In this review, the pathological basis for CI in various stages of MS was reviewed and revealed to provide a basis for the treatment. Role of phosphodiesterase 7B1 (PDE7B1) inhibitors in treating CI related to MS were also stated in this review. The literature for this review was collected from PubMed and Embase.


How to cite this article:
Balsundaram A, Chellathai D. Phosphodiesterase 7B1 as therapeutic target for treatment of cognitive dysfunctions in multiple sclerosis.J Pharmacol Pharmacother 2018;9:126-130


How to cite this URL:
Balsundaram A, Chellathai D. Phosphodiesterase 7B1 as therapeutic target for treatment of cognitive dysfunctions in multiple sclerosis. J Pharmacol Pharmacother [serial online] 2018 [cited 2019 Mar 23 ];9:126-130
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2018;volume=9;issue=3;spage=126;epage=130;aulast=Balsundaram;type=0